PDL BIOPHARMA, INC. Form 8-K September 15, 2009

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 14, 2009

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756

(Commission File Number)

Delaware (State or Other Jurisdiction

94-3023969 (I.R.S. Employer

Edgar Filing: PDL BIOPHARMA, INC. - Form 8-K

of Incorporation) Identification No.)

932 Southwood Boulevard

Incline Village, Nevada 89451

(Address of principal executive offices, with zip code)

(775) 832-8500

(Company s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: PDL BIOPHARMA, INC. - Form 8-K

Item 7.01. Regulation FD Disclosure.

On September 16, 2009, the Company will make a presentation at the BioCentury NewsMakers in the Biotech Industry Conference in New York City (the BioCentury NewsMakers Conference). A copy of the Company s presentation materials has been posted on the Company s website and is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 BioCentury NewsMakers Conference presentation to be given on September 16, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC. (Company)

By: /s/ John P. McLaughlin John P. McLaughlin President and Chief Executive Officer

Dated: September 14, 2009

EXHIBIT INDEX

Exhibit No.

DescriptionBioCentury NewsMakers Conference presentation to be given on September 16, 2009. 99.1